These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 28838177)

  • 1. The Switch From Trivalent to Bivalent Oral Poliovirus Vaccine in the South-East Asia Region.
    Bahl S; Hasman A; Eltayeb AO; James Noble D; Thapa A
    J Infect Dis; 2017 Jul; 216(suppl_1):S94-S100. PubMed ID: 28838177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines-Lessons Learned From the Global Perspective.
    Ramirez Gonzalez A; Farrell M; Menning L; Garon J; Everts H; Hampton LM; Dolan SB; Shendale S; Wanyoike S; Veira CL; Châtellier GMD; Kurji F; Rubin J; Boualam L; Chang Blanc D; Patel M
    J Infect Dis; 2017 Jul; 216(suppl_1):S183-S192. PubMed ID: 28838179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introduction of Inactivated Poliovirus Vaccine and Trivalent Oral Polio Vaccine/Bivalent Oral Polio Vaccine Switch in the African Region.
    Tevi-Benissan C; Okeibunor J; du Châtellier GM; Assefa A; Biey JN; Cheikh D; Eshetu M; Anya BP; Dao H; Nasir Y; Akanmori BD; Mihigo R
    J Infect Dis; 2017 Jul; 216(suppl_1):S66-S75. PubMed ID: 28838178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience With Inactivated Polio Vaccine Introduction and the "Switch" From Trivalent to Bivalent Oral Polio Vaccine in the World Health Organization's Western Pacific Region.
    Gurung S; Harris JB; Eltayeb AO; Hampton LM; Diorditsa S; Avagyan T; Schluter WW
    J Infect Dis; 2017 Jul; 216(suppl_1):S101-S108. PubMed ID: 28838170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Communications, Immunization, and Polio Vaccines: Lessons From a Global Perspective on Generating Political Will, Informing Decision-Making and Planning, and Engaging Local Support.
    Menning L; Garg G; Pokharel D; Thrush E; Farrell M; Kodio FK; Veira CL; Wanyoike S; Malik S; Patel M; Rosenbauer O
    J Infect Dis; 2017 Jul; 216(suppl_1):S24-S32. PubMed ID: 28838189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory Aspects of Sabin Type 2 Withdrawal From Trivalent Oral Poliovirus Vaccine: Process and Lessons Learned.
    Decina D; Fournier-Caruana J; Takane M; Ostad Ali Dehaghi R; Sutter R
    J Infect Dis; 2017 Jul; 216(suppl_1):S46-S51. PubMed ID: 28838164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introduction of Inactivated Polio Vaccine, Withdrawal of Type 2 Oral Polio Vaccine, and Routine Immunization Strengthening in the Eastern Mediterranean Region.
    Fahmy K; Hampton LM; Langar H; Patel M; Mir T; Soloman C; Hasman A; Yusuf N; Teleb N
    J Infect Dis; 2017 Jul; 216(suppl_1):S86-S93. PubMed ID: 28838199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
    Duintjer Tebbens RJ; Hampton LM; Thompson KM
    BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Dedicated Mobile Teams and Polio Volunteer Community Mobilizers to Increase Access to Zero-Dose Oral Poliovirus Vaccine and Routine Childhood Immunizations in Settlements at High Risk for Polio Transmission in Northern Nigeria.
    Ongwae KM; Bawa SB; Shuaib F; Braka F; Corkum M; Isa HK
    J Infect Dis; 2017 Jul; 216(suppl_1):S267-S272. PubMed ID: 28838155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematization of the Introduction of IPV and Switch from tOPV to bOPV in the Americas.
    Pedreira C; Thrush E; Jauregui B
    J Infect Dis; 2017 Jul; 216(suppl_1):S76-S85. PubMed ID: 28838161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polio endgame: the global switch from tOPV to bOPV.
    Garon J; Seib K; Orenstein WA; Ramirez Gonzalez A; Chang Blanc D; Zaffran M; Patel M
    Expert Rev Vaccines; 2016 Jun; 15(6):693-708. PubMed ID: 26751187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polio Endgame: Lessons Learned From the Immunization Systems Management Group.
    Zipursky S; Vandelaer J; Brooks A; Dietz V; Kachra T; Farrell M; Ottosen A; Sever JL; Zaffran MJ
    J Infect Dis; 2017 Jul; 216(suppl_1):S9-S14. PubMed ID: 28838174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
    Orenstein WA;
    Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polio endgame: the global introduction of inactivated polio vaccine.
    Patel M; Zipursky S; Orenstein W; Garon J; Zaffran M
    Expert Rev Vaccines; 2015 May; 14(5):749-62. PubMed ID: 25597843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global Polio Eradication,The Journey So Far.
    Thacker N; Yewale VN; Pathak A
    Indian Pediatr; 2016 Aug; 53 Suppl 1():S61-S64. PubMed ID: 27771642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Financial Support to Eligible Countries for the Switch From Trivalent to Bivalent Oral Polio Vaccine-Lessons Learned.
    Shendale S; Farrell M; Hampton LM; Harris JB; Kachra T; Kurji F; Patel M; Ramirez Gonzalez A; Zipursky S
    J Infect Dis; 2017 Jul; 216(suppl_1):S57-S65. PubMed ID: 28838171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The new polio eradication end game: rationale and supporting evidence.
    Sutter RW; Platt L; Mach O; Jafari H; Aylward RB
    J Infect Dis; 2014 Nov; 210 Suppl 1():S434-8. PubMed ID: 25316865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposing of Excess Vaccines After the Withdrawal of Oral Polio Vaccine.
    Wanyoike S; Ramirez Gonzalez A; Dolan SB; Garon J; Veira CL; Hampton LM; Chang Blanc D; Patel MM
    J Infect Dis; 2017 Jul; 216(suppl_1):S202-S208. PubMed ID: 28838168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introduction of Inactivated Poliovirus Vaccine in National Immunization Program and Polio Endgame Strategy.
    ; Vashishtha VM; Choudhary J; Yadav S; Unni JC; Jog P; Kamath SS; Sachdeva A; Srirampur S; Prajapati B; Parekh BJ
    Indian Pediatr; 2016 Aug; 53 Suppl 1():S65-S69. PubMed ID: 27133231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Polio vaccines, eradication and posterradication].
    Salmerón García F; Portela Moreira A; Soler Soneira M; López Hernández S; Chamorro Somoza Díaz-Sarmiento M; Pérez González I; Rubio Gómez MI; Pérez González A; Sagredo Rodríguez A; Ruiz Antúnez S; Timón Jiménez M; Frutos Cabanillas G
    Rev Esp Salud Publica; 2013; 87(5):497-505. PubMed ID: 24322286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.